• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Cadre Holdings Inc.

    11/14/25 4:15:11 PM ET
    $CDRE
    Industrial Specialties
    Health Care
    Get the next $CDRE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    CADRE HOLDINGS, INC.

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)


    12763L105

    (CUSIP Number)


    Robert L. Lawrence
    Kane Kessler, P.C., 600 3rd Avenue, 35th Floor
    New York, NY, 10016
    (212) 541-6222

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    11/10/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    12763L105


    1 Name of reporting person

    Warren B. Kanders
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    13,013,061.00
    8Shared Voting Power

    23,450.00
    9Sole Dispositive Power

    13,013,061.00
    10Shared Dispositive Power

    23,450.00
    11Aggregate amount beneficially owned by each reporting person

    13,036,511.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    30.9 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Footnote to Rows 7 and 9: Consists of (i) 1,258,584 shares held by Warren B. Kanders, (ii) 1,305,650 shares held by Warren B. Kanders Roth IRA, (iii) 10,216,192 shares held by Kanders SAF, LLC ("Kanders SAF"); and (iv) options to purchase an aggregate of 232,635 shares of common stock which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are presently exercisable or exercisable within 60 days of the date hereof; and excludes (i) 229,797 shares underlying stock options to purchase shares of common stock which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are not presently exercisable or exercisable within 60 days of the date hereof; and (ii) 71,481 shares underlying restricted common units award which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are not presently vested or vesting within 60 days of the date hereof. Mr. Kanders is the sole member and manager of Kanders SAF, and accordingly all of the shares of the Issuer's common stock held by Kanders SAF may be deemed to be beneficially owned by Mr. Kanders. Footnote to Rows 8 and 10: Consists of 23,450 shares held by Allison Kanders Roth IRA. Allison Kanders is the wife of Mr. Kanders, and accordingly all of the shares of the Issuer's common stock held by Allison Kanders may be deemed to be beneficially owned by Mr. Kanders. Footnote to Row 11: The amount reported above as being beneficially owned by Mr. Kanders (i) includes, without duplication, the shares reported in Rows 7 and 9 plus the shares reported in Rows 8 and 10; and (ii) excludes, without duplication, (a) 229,797 shares underlying stock options to purchase shares of common stock which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are not presently exercisable or exercisable within 60 days of the date hereof; and (b) 71,481 shares underlying restricted common units award which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are not presently vested or vesting within 60 days of the date hereof. Footnote to Row 13: The percentage of shares of common stock reported as being beneficially owned by Mr. Kanders is based upon 42,245,528 shares of common stock outstanding as of the date hereof, which includes: (i) 40,663,844 shares of common stock outstanding as of November 3, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission on November 4, 2025; (ii) options to purchase an aggregate of 232,635 shares of common stock which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are presently exercisable or exercisable within 60 days of the date hereof; and (iii) an aggregate of 1,349,049 shares of common stock outstanding upon the vesting on November 10, 2025 of restricted stock units awards previously granted under the Issuer's 2021 Stock Incentive Plan.


    SCHEDULE 13D

    CUSIP No.
    12763L105


    1 Name of reporting person

    Kanders SAF, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    10,216,192.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    10,216,192.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    10,216,192.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    24.3 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Footnote to Rows 7, 9 and 11: Mr. Kanders is the sole member and manager of Kanders SAF, and accordingly may be deemed to beneficially own all of the shares of the Company's common stock held by Kanders SAF. Footnote to Row 13: The percentage of shares of common stock reported as being beneficially owned by Kanders SAF is based upon 42,012,893 shares of common stock outstanding as of the date hereof, which includes: (i) 40,663,844 shares of common stock outstanding as of November 3, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission on November 4, 2025; and (ii) an aggregate of 1,349,049 shares of common stock outstanding upon the vesting on November 10, 2025 of restricted stock units awards previously granted under the Issuer's 2021 Stock Incentive Plan.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common stock, par value $0.0001 per share
    (b)Name of Issuer:

    CADRE HOLDINGS, INC.
    (c)Address of Issuer's Principal Executive Offices:

    13386 International Pkwy, Jacksonville, FLORIDA , 32218.
    Item 2.Identity and Background
    (a)
    (i) Warren B. Kanders; and (ii) Kanders SAF (collectively, the "Reporting Persons")
    (b)
    The address of the principal business office of the Reporting Persons is 250 Royal Palm Way, Suite 201, Palm Beach, Florida 33480.
    (c)
    Mr. Kanders' present principal occupation or employment is (i) serving as Chief Executive Officer and Chairman of the Board of Directors of the Issuer; (ii) serving as the Executive Chairman of the Board of Directors of Clarus Corporation with a principal address of 2084 East 3900 South, Salt Lake City, Utah 84124; and (iii) serving as President of Kanders & Company, Inc. with a principal address of 250 Royal Palm Way, Suite 201, Palm Beach, Florida, 33480.
    (d)
    During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Mr. Kanders is a citizen of the United States. Kanders SAF is a Delaware limited liability company.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The Reporting Persons acquired the shares of the Issuer's common stock (i) upon an in-kind, pro rata distribution by Maui Holdings, LLC ("Maui Holdings") of all shares of the Issuer's common stock then owned by Maui Holdings to its members, in accordance with the limited liability company operating agreement of Maui Holdings; and (ii) upon the vesting and settlement of equity awards granted under the Issuer's 2021 Stock Incentive Plan.
    Item 4.Purpose of Transaction
     
    On November 10, 2025, Mr. Kanders acquired an aggregate of 1,213,000 shares of the Issuer's common stock upon the vesting and settlement of a restricted stock units award previously granted under the Issuer's 2021 Stock Incentive Plan, following satisfaction of a vesting condition requiring that the "Fair Market Value" (as defined in that plan) of the Issuer's common stock equal or exceed $40.00 per share for twenty consecutive trading days. The Reporting Persons previously reported beneficial ownership on Schedule 13G pursuant to Rule 13d-1(d). Following the November 10, 2025 vesting and settlement described above, the Reporting Persons are filing this Schedule 13D. Subject to market conditions and other factors, the Reporting Persons may from time to time acquire additional securities of the Issuer or dispose of some or all of the securities of the Issuer beneficially owned by the Reporting Persons in open-market transactions, privately negotiated transactions or otherwise, in each case in accordance with applicable securities laws and the Issuer's policies. Except as described in this Item 4, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the matters set forth in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to change their plans and intentions at any time and to take any actions they deem appropriate with respect to their investment in the Issuer.
    Item 5.Interest in Securities of the Issuer
    (a)
    As of the date of this Schedule 13D, Mr. Kanders may be deemed to be the beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act of 1934, as amended) of 13,036,511 shares of common stock, constituting approximately 30.9% of the outstanding shares of common stock, which is comprised of: (i) 1,258,584 shares held by Warren B. Kanders, (ii) 1,305,650 shares held by Warren B. Kanders Roth IRA, (iii) 10,216,192 shares held by Kanders SAF; (iv) options to purchase an aggregate of 232,635 shares of common stock which were previously granted under the Company's 2021 Stock Incentive Plan and that are presently exercisable or exercisable within 60 days of the date hereof; and (v) 23,450 shares of common stock held by Allison Kanders Roth IRA. The amount reported above as being beneficially owned by Mr. Kanders excludes (i) 229,797 shares underlying stock options to purchase shares of common stock which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are not presently exercisable or exercisable within 60 days of the date hereof; and (ii) 71,481 shares underlying restricted stock units award which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are not presently vested or vesting within 60 days of the date hereof. The percentage of shares of common stock reported as being beneficially owned by Mr. Kanders is based upon 42,245,528 shares of common stock outstanding as of the date hereof, which includes: (i) 40,663,844 shares of common stock outstanding as of November 3, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission on November 4, 2025; (ii) options to purchase an aggregate of 232,635 shares of common stock which were previously granted under the Issuer's 2021 Stock Incentive Plan and that are presently exercisable or exercisable within 60 days of the date hereof; and (iii) an aggregate of 1,349,049 shares of common stock outstanding upon the vesting on November 10, 2025 of restricted stock units awards previously granted under the Issuer's 2021 Stock Incentive Plan. Of the 13,036,511 shares beneficially owned by the Reporting Persons, Kanders SAF has granted a security interest in an aggregate of 3,750,000 shares of the Issuer's common stock beneficially owned by the Reporting Persons in favor of Texas Capital Bank pursuant to the Loan Agreement described in Item 6.
    (b)
    Of the shares of common stock reported as being beneficially owned by Mr. Kanders, he (i) has sole power to vote or direct the vote and to dispose or direct the disposition of 13,013,061 shares of common stock, including 10,216,192 shares held by Kanders SAF, as its sole member and manager of Kanders SAF; and (ii) shares with his wife, the power to vote or direct the vote and to dispose or direct the disposition of the 23,450 shares held by the Allison Kanders Roth IRA.
    (c)
    Except as set forth below, no transactions in the shares of the Issuer's common stock have been affected by the Reporting Persons during the last 60 days. On November 10, 2025, Mr. Kanders acquired an aggregate of 1,213,000 shares of the Issuer's common stock upon the vesting and settlement of a restricted stock units award previously granted under the Issuer's 2021 Stock Incentive Plan, following satisfaction of a vesting condition requiring that the "Fair Market Value" (as defined in that plan) of the Issuer's common stock equal or exceed $40.00 per share for twenty consecutive trading days.
    (d)
    No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends or sale proceeds with respect to the Issuer's common stock reported herein; provided that, with respect to the shares of the Issuer's common stock beneficially owned by the Allison Kanders Roth IRA, Allison Kanders shares with Mr. Kanders the right to receive and the power to direct the receipt of dividends and sale proceeds with respect to such securities.
    (e)
    N/A
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Kanders SAF has granted a security interest in an aggregate of 3,750,000 shares of the Issuer's common stock beneficially owned by it in favor of Texas Capital Bank pursuant to that certain Loan and Security Agreement, dated December 1, 2022 (the "Loan Agreement"). Prior to any event of default, the lender has no right to vote or dispose of the shares subject to the security interest. Upon an event of default, the lender may be entitled to foreclose on such shares and, subject to the Loan Agreement and applicable law, exercise voting and/or dispositive power with respect thereto. Other than the foregoing, the Reporting Persons have no contracts, arrangements, understandings or relationships with any person with respect to any securities of the Issuer that are required to be disclosed pursuant to Item 6.
    Item 7.Material to be Filed as Exhibits.
     
    Joint Filing Agreement, dated November 14, 2025, by and among the Reporting Persons.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Warren B. Kanders
     
    Signature:/s/ Warren B. Kanders
    Name/Title:Warren B. Kanders
    Date:11/14/2025
     
    Kanders SAF, LLC
     
    Signature:/s/ Warren B. Kanders
    Name/Title:Warren B. Kanders / Manager
    Date:11/14/2025
    Get the next $CDRE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDRE

    DatePrice TargetRatingAnalyst
    8/13/2025$26.00Neutral → Underperform
    BofA Securities
    6/13/2025$38.00Buy → Neutral
    BofA Securities
    2/21/2024$32.00 → $38.00Buy
    ROTH MKM
    1/22/2024Outperform → Mkt Perform
    Raymond James
    9/6/2022$30.00Buy
    BofA Securities
    8/31/2022$32.00Buy
    Jefferies
    3/11/2022$25.00 → $27.00Outperform
    Raymond James
    11/29/2021$24.00Buy
    Lake Street
    More analyst ratings

    $CDRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cadre Holdings Subsidiary Is Awarded $50 Million Contract with the Department of War

    Company will Provide Mission-Critical Blast Exposure Monitoring System to Preserve and Maintain Readiness for Warfighters Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today that its subsidiary Med-Eng, LLC has been awarded a 5-year Indefinite Delivery / Indefinite Quantity (ID/IQ) contract with a maximum value of $50 million by the United States Department of War (DoW) to deliver and support the Blast Exposure Monitoring (BEMO) Program. The BEMO systems, including sensor hardware and related s

    11/19/25 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Reports Third Quarter 2025 Financial Results

    Grew Quarterly Net Sales 42% and Gross Profit 66% Year-Over-Year Increased Quarterly Adjusted EBITDA of $29.8 Million and Expanded Adjusted EBITDA Margin of 19.1% Organic Backlog Increased $20 Million from Q2 to Q3 Med-Eng Awarded $50 Million IDIQ with DoD – First PO issued for $10 Million to be Shipped in 2026 Agrees to Acquire TYR Tactical, Leading Provider of Plate Carriers, Vests, Hard Armor, and Shields Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today its consolidated operating results f

    11/4/25 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings to Acquire TYR Tactical

    Leading Provider of Plate Carriers, Vests, Hard Armor, and Shields to Tactical Teams Expected to be Immediately Accretive and Advances Strategic Focus on Mission-Critical Products with High Margins, Strong Cash Flows Provides Significant Entry into New Markets, Particularly in European Military and Defense Management Will Host a Conference Call at 10 a.m. ET to Discuss the Transaction Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today it has entered into a definitive agreement to acquire

    10/29/25 6:00:00 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cadre Holdings downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cadre Holdings from Neutral to Underperform and set a new price target of $26.00

    8/13/25 8:01:40 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cadre Holdings from Buy to Neutral and set a new price target of $38.00

    6/13/25 7:45:51 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    ROTH MKM reiterated coverage on Cadre Holdings with a new price target

    ROTH MKM reiterated coverage of Cadre Holdings with a rating of Buy and set a new price target of $38.00 from $32.00 previously

    2/21/24 9:51:23 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Cadre Holdings Inc.

    SCHEDULE 13D/A - Cadre Holdings, Inc. (0001860543) (Subject)

    11/19/25 4:15:17 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by Cadre Holdings Inc.

    144 - Cadre Holdings, Inc. (0001860543) (Subject)

    11/17/25 6:41:32 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form SCHEDULE 13D filed by Cadre Holdings Inc.

    SCHEDULE 13D - Cadre Holdings, Inc. (0001860543) (Subject)

    11/14/25 4:15:11 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO AND CHAIRMAN Kanders Warren B sold $52,413,699 worth of shares (1,343,941 units at $39.00), decreasing direct ownership by 100% to 1,546 units (SEC Form 4)

    4 - Cadre Holdings, Inc. (0001860543) (Issuer)

    11/19/25 4:15:15 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    PRESIDENT Williams Brad sold $1,193,879 worth of shares (27,370 units at $43.62), decreasing direct ownership by 26% to 78,719 units (SEC Form 4)

    4 - Cadre Holdings, Inc. (0001860543) (Issuer)

    11/17/25 4:15:27 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    CEO AND CHAIRMAN Kanders Warren B converted options into 2,000,000 shares and covered exercise/tax liability with 787,000 shares, increasing direct ownership by 2,661% to 1,258,584 units (SEC Form 4)

    4 - Cadre Holdings, Inc. (0001860543) (Issuer)

    11/12/25 4:15:15 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Leadership Updates

    Live Leadership Updates

    View All

    Cadre Holdings Appoints Gianmaria Delzanno to its Board of Directors

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced the appointment of Gianmaria Delzanno to its board of directors, effective as of January 13, 2025. Current Director Nicholas Sokolow, who joined the board of Cadre's predecessor in July of 2012, will retire from the Company's board, effective as of January 31, 2025. Upon Mr. Sokolow's departure, Mr. Delzanno will replace Mr. Sokolow as the lead independent director and will also serve as Chairman of the Nominating and Corporate Governance Committee as

    1/13/25 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Appoints Deborah DeCotis to its Board of Directors

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety and survivability equipment for first responders, announced the appointment of Deborah DeCotis to its board of directors, effective immediately. With Ms. DeCotis' appointment, the Board will expand to five directors, four of whom are independent. Ms. DeCotis will also serve on the Company's Compensation Committee. Ms. DeCotis has over 45 years of financial, advisory and business operations experience with a successful track record of leadership across multiple global institutions and industries. She currently serves as Advisory Director at Morgan Stanley & Co., Inc.

    4/12/22 8:30:00 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    ElectraMeccanica Appoints Automotive Veteran, William Quigley III, to Board of Directors

    VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- ElectraMeccanica Vehicles Corp. (NASDAQ:SOLO) ("ElectraMeccanica" or the "Company"), a designer and manufacturer of electric vehicles revolutionizing the urban driving experience, today announced the appointment of William (Bill) Quigley III to its Board of Directors. Mr. Quigley is an accomplished leader with a proven track record in large enterprises specific to the automotive industry. With 30 plus years in the industry, Bill's career has included the following key roles: Executive Vice President and Chief Financial Officer at Dana Holding Corporation, an automotive, commercial vehicle and off-highway driveline, sealing an

    4/7/22 8:05:00 AM ET
    $CDRE
    $SOLO
    Industrial Specialties
    Health Care
    Auto Manufacturing
    Consumer Discretionary

    $CDRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cadre Holdings Inc.

    SC 13G/A - Cadre Holdings, Inc. (0001860543) (Subject)

    11/12/24 9:50:14 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Cadre Holdings Inc.

    SC 13G - Cadre Holdings, Inc. (0001860543) (Subject)

    2/14/24 7:58:49 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Cadre Holdings Inc. (Amendment)

    SC 13G/A - Cadre Holdings, Inc. (0001860543) (Subject)

    2/12/24 4:15:31 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    $CDRE
    Financials

    Live finance-specific insights

    View All

    Cadre Holdings Reports Third Quarter 2025 Financial Results

    Grew Quarterly Net Sales 42% and Gross Profit 66% Year-Over-Year Increased Quarterly Adjusted EBITDA of $29.8 Million and Expanded Adjusted EBITDA Margin of 19.1% Organic Backlog Increased $20 Million from Q2 to Q3 Med-Eng Awarded $50 Million IDIQ with DoD – First PO issued for $10 Million to be Shipped in 2026 Agrees to Acquire TYR Tactical, Leading Provider of Plate Carriers, Vests, Hard Armor, and Shields Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today its consolidated operating results f

    11/4/25 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings to Acquire TYR Tactical

    Leading Provider of Plate Carriers, Vests, Hard Armor, and Shields to Tactical Teams Expected to be Immediately Accretive and Advances Strategic Focus on Mission-Critical Products with High Margins, Strong Cash Flows Provides Significant Entry into New Markets, Particularly in European Military and Defense Management Will Host a Conference Call at 10 a.m. ET to Discuss the Transaction Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today it has entered into a definitive agreement to acquire

    10/29/25 6:00:00 AM ET
    $CDRE
    Industrial Specialties
    Health Care

    Cadre Holdings Announces Third Quarter 2025 Earnings and Conference Call Information

    Cadre Holdings, Inc. (NYSE:CDRE) ("Cadre" or "the Company"), a global leader in the manufacturing and distribution of safety equipment and other related products for the law enforcement, first responder, military and nuclear markets, announced today that it plans to release financial results for the third quarter that ended on September 30, 2025, on Tuesday, November 4, 2025, after the close of market trading. The company has scheduled a conference call to discuss these results on Wednesday, November 5, 2025, at 10:00 a.m. ET. The conference call will feature remarks by Warren Kanders, CEO and Chairman of the Board; Brad Williams, President; and Blaine Browers, Chief Financial Officer. To

    10/22/25 4:15:00 PM ET
    $CDRE
    Industrial Specialties
    Health Care